{
    "id": "1244",
    "question": "The parents of a 16-year-old boy with type 1 diabetes mellitus present requesting information about the drug, exenatide, an injectable drug that only needs to be administered once a week. The patient\u2019s blood glucose levels have been difficult to control on his current insulin regimen due to poor adherence to recommended therapy, and he has had difficulty putting on weight despite eating copiously. The patient is afebrile and his vital signs are within normal limits. His body mass index (BMI) is 19 kg/m2. Which of the following best describes why the patient should not be switched to exenatide?",
    "options": {
        "A": "Insulin production by the pancreas is insufficient for exenatide to be effective.",
        "B": "Exenatide suppresses glucagon secretion, which increases the risk of hypoglycemia.",
        "C": "Suppression of appetite makes it even harder for him to gain weight.",
        "D": "Exenatide is contraindicated in children below 18 years."
    },
    "answer": "A",
    "predict": "To determine why the patient should not be switched to exenatide, let's analyze the given information step by step: 1. **Patient's condition**: The patient has type 1 diabetes mellitus, which means his body is unable to produce insulin on its own. He is experiencing difficulty controlling his blood glucose levels with his current insulin regimen, indicating a need for alternative therapy. 2. **Current treatment goal**: The patient is having trouble gaining weight, despite eating copiously, which is a common challenge for patients with type 1 diabetes, as they often experience hyperglycemia (high blood sugar) due to insufficient insulin production. 3. **Exenatide's mechanism of action**: Exenatide is a glucagon-like peptide-1 (GLP-1) receptor agonist that stimulates insulin release in a glucose-dependent manner and suppresses glucagon secretion. This action helps to lower blood glucose levels. 4. **Patient's BMI**: The patient's BMI is 19 kg/m2, which falls into the underweight category. GLP-1 receptor agonists like exenatide have been shown to promote weight gain in patients with type 2 diabetes, but their effect on weight in patients with type 1 diabetes is less clear. Given these points, let's evaluate the options: - A: Insulin production by the pancreas is insufficient for exenatide to be effective. This is incorrect because exenatide does not require insulin production; it works by mimicking the action of insulin. - B: Exenatide suppresses glucagon secretion, which increases the risk of hypoglycemia. This is incorrect because exenatide actually suppresses glucagon secretion, which can help prevent hyperglycemia, not hypoglycemia. - C: Suppression of appetite makes it even harder for him to gain weight. This is a correct answer. GLP-1 receptor agonists like exenatide are known to suppress appetite and promote weight gain in patients with type 2 diabetes. However, in a patient with type 1 diabetes, this effect may not be beneficial, as they often struggle to gain weight due to the disease itself. - D: Exenatide is contraindicated in children below 18 years. This is incorrect because exenatide's safety and efficacy in children have been studied, and it is approved for use in patients with type 2 diabetes, but its use in children with type 1 diabetes is not specifically contraindicated. Therefore, the best answer is: {\"step_by_step_thinking\": \"Exenatide may not be beneficial for a patient with type 1 diabetes who is having trouble gaining weight, as it suppresses appetite and may not help with weight gain in this specific population.\", \"answer_choice\": \"C\"}",
    "snippets": [],
    "scores": [],
    "execution_time": 27.843743324279785
}